Professor, Internal Medicine, Div. of Cardiology Washington University in St. Louis

Printed as of 4/18/2024

Disclosures

Personal Commercial (2)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---------------|---|--------------------------|---------------------|
| Self | | | |
| GE Healthcare | Research/Research Grants ‡ A phase 3, open-label, multicentre study of Flurpiridaz (18F) and PET for assessment of myocardial perfusion in patients referred for invasive coronary angiography because of suspected CAD. | Significant (>= \$5,000) | Noninvasive Imaging |
| MedTrace | Officer, Director, Trustee, or other Fiduciary Role | Significant (>= \$5,000) | Noninvasive Imaging |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (2)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------|---|
| Self | | | |
| ASNC | Officer, Director, Trustee, or other Fiduciary Role | None (\$0) | Noninvasive Imaging |
| Society of Nuclear Medecine, Cardiovascular Council | Officer, Director, Trustee, or other Fiduciary Role | None (\$0) | Noninvasive Imaging Prevention Vascular Medicine |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 8/16/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/16/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/16/2023

URL for full agreement: http://disclosures. acc. org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 8/16/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.